Evidence map›Paper›PMID 32340351›Full record

ArticleMolecules (Basel, Switzerland)2020

Cytotoxic Activities and Molecular Mechanisms of the Beauvericin and Beauvericin G

Haet Nim Lim, Jun-Pil Jang, Hee Jeong Shin, Jae-Hyuk Jang, Jong Seog Ahn, Hye Jin Jung

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Haet Nim LimDepartment of Life Science and Biochemical Engineering, Sun Moon University, Asan 31460, Korea.
Jun-Pil JangAnticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Korea.
Hee Jeong ShinDepartment of Life Science and Biochemical Engineering, Sun Moon University, Asan 31460, Korea.
Jae-Hyuk JangNatural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Korea.ORCID 0000-0002-4363-4252
Jong Seog AhnAnticancer Agent Research Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Korea.ORCID 0000-0001-5166-4358
Hye Jin JungDepartment of Life Science and Biochemical Engineering, Sun Moon University, Asan 31460, Korea.ORCID 0000-0003-3145-9300
Korea Research Institute of Bioscience and Biotechnology · KRSun Moon University · KRAdvanced Institute of Convergence Technology · KR

Funding

Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education NRF-2016R1D1A1B03932956International Joint Research Project of the NST (National Research Council of Science & Technology) ASIA-16-001NRF grant funded by the Ministry of Science and ICT NRF-2019R1A2C1009033
6 · The paper itself

Abstract

Melanoma is the most serious type of skin cancer and remains highly drug-resistant. Therefore, the discovery of novel effective agents against melanoma is in high demand. Herein, we investigated the cytotoxic activities in melanoma cells and underlying molecular mechanisms of beauvericin (BEA) and its analogue beauvericin G

Indexed as

Antineoplastic AgentsApoptosisBiological ProductsBiomarkersCell Line, TumorCell MovementCell SurvivalDepsipeptidesHumansMelanomaMolecular StructureSignal TransductionAntineoplastic AgentsbeauvericinBiological ProductsBiomarkersDepsipeptidesapoptosisbeauvericinbeauvericin G1melanomamicrobial product

Identifiers

PMID32340351
PMCPMC7221855
OpenAlexW3018023910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.